Prior to Medical Innovation Day, all participants must submit an abstract about their research. You submit your abstract upon registration.

Instructions:

• The abstract should be an appetizer and a popular description of the innovative idea without revealing details
• Font: Times New Roman, size 12
• Max 1000 characters including spaces
• Format: .doc, .docx or .pdf

Also, participants must submit/bring a Power Point presentation at Medical Innovation Day.

Instructions:

• 6 slides which can be presented in 5-6 minutes

Here are some suggestions for slides:

• Title – perhaps also acronym for idea/unmet need (1-2 slides)
• Market potential (1-2 slides)
• Raw outline of scientific basis/principle (1-2 slides)
• Handling of intellectual properties
• Development plan – preclinical – clinical etc.
• Investment required based on raw budget
• Why should anyone invest in your idea?

Please have a first draft of your presentation ready for the Medical Innovation Day.

You are welcome to contact Ulf Simonsen (us@biomed.au.dk) for comments on your presentation. 

Moderators:

• Prof. Ulf Simonsen, Dept. of Biomedicine, AU
• Associate professor Simon Tilma Vistisen, Dept. of Clinical Medicine, AU

Panel members for the sessions:
We are proud to be able to present a highly esteemed and diverse panel of experts, advisors and stakeholders. The panel is put together in order to give feedback on the projects presented and to give advise on how to move forward with commercialization of the innovative idea in question. The confirmed panelists are:

• Steen Bennike Mortensen, InnovationFund Denmark
  Steen is among others responsible for the evaluation of Grand Solution applications submitted to the InnovationFund.
• Monica Milter Ehlers, InnovationFund Denmark
  Monica is an Investment Officer in Life-Sciences at InnovationFund Denmark.
• Trine Bartholdy, BioInnovation Institute
  Trine is Chief Innovation Officer at BII and has +20 years of life science experience and a background within Life Science Venture Capital from Sunstone Capital and the Pharmaceutical industry working with strategic therapeutics portfolio management, followed by digital health at Novo Nordisk.
• Tugrul Ozdemir, Novo Seeds
  Tugrul is an Associate of the Novo Seeds. Previously, he worked as a postdoctoral researcher in the Department of Pharmacology at the University of Oxford, and as a VC fellow at Ysios Capital, where he analyzed deal flow opportunities and supported due diligence and management processes of biotechnology companies at various stages of development
• Sten Verland, Sunstone
  Sten Verland is one of the three co-founders of Sunstone Life Science Ventures and focuses, in particular, on investment opportunities related to immuno-oncology, autoimmune diseases, and orphan diseases. During his career, Sten has been a serial entrepreneur and business angel and co-founded 10 start-ups, primarily in the biotech and CRO fields. While at Sunstone, Sten has played a key role in executing three M&A exits (Rigontec, Action Pharma, and Zymenex) and one IPO (Orphazyme). Sten holds a master’s degree in Biology and Mathematics and a Ph.D. in Immunology from the University of Copenhagen. Sten serves as a Danish Venture Capital and Private Equity Association (DVCA) board member.
• Erik Vinther, Marigold Innovation
  Erik Vinther is a Senior Consultant at Marigold Innovation where he is consulting on areas such as commercial strategy and implementation, marketing and alignment of development plans with commercial goals.